Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Intravitreal Administration of Avacincaptad Pegol in a Nonhuman Primate Model of Dry Age-Related Macular Degeneration.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 101626369 Publication Model: Print Cited Medium: Internet ISSN: 2052-1707 (Electronic) Linking ISSN: 20521707 NLM ISO Abbreviation: Pharmacol Res Perspect Subsets: MEDLINE
- Publication Information:
Original Publication: [Hoboken, NJ] : John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics, [2013]-
- Subject Terms:
- Abstract:
The lack of effective treatments for dry age-related macular degeneration (AMD) is in part due to a lack of a preclinical animal model that recapitulates features of the clinical state including macular retinal pigment epithelium (RPE) degeneration, also known as geographic atrophy (GA). A nonhuman primate model of GA was developed and its responsiveness to an approved treatment, avacincaptad pegol (ACP), a complement C5 inhibitor, was evaluated. Intravitreal (ivt) administration of sodium iodate (SI) into one eye of male Macaca fascicularis leads to retinal areas (mm 2 ) of hyper- or hypo-autofluorescence. Qualitative changes to the retinal structure over time were observed with spectral domain optical coherence tomography (OCT). Six days after SI administration, prior to treatment, mean (± SEM) GA of all eyes was 8.2 ± 1.8 mm 2 . Following randomization to treatment groups, either vehicle or ACP was ivt injected and treatment was continued every 4 weeks, for a total of four treatments. Sixteen weeks after SI administration, the GA area in vehicle-treated eyes was 18.9 ± 6.6 mm 2 , whereas GA in ACP-treated eyes was 11.4 ± 4.0 mm 2 , a reduction by about 36%. Increased, followed by decreased, overall macular thickness was observed with OCT over time following SI administration. Treatment with ACP did not change alter macular thickness thinning. Geographic atrophy-like lesions that expand over time are observed following SI administration. The current macaque model could be utilized to further explore the mechanism of dry AMD and to develop more novel therapeutics.
(© 2024 The Author(s). Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.)
- References:
Sci Rep. 2018 May 9;8(1):7348. (PMID: 29743491)
Curr Mol Med. 2018;18(6):352-364. (PMID: 30421676)
Lancet. 2023 Oct 21;402(10411):1449-1458. (PMID: 37696275)
Pharm Res. 2012 Dec;29(12):3251-72. (PMID: 22752935)
Sci Rep. 2019 Oct 30;9(1):15696. (PMID: 31666618)
Invest Ophthalmol Vis Sci. 2005 Feb;46(2):683-91. (PMID: 15671300)
Adv Exp Med Biol. 2010;703:127-35. (PMID: 20711711)
Cell. 2019 Feb 21;176(5):1222-1237.e22. (PMID: 30712875)
Expert Rev Ophthalmol. 2014;9(4):285-295. (PMID: 35600070)
Expert Opin Pharmacother. 2018 Apr;19(5):471-481. (PMID: 29542350)
Invest Ophthalmol Vis Sci. 2018 Mar 20;59(4):AMD143-AMD151. (PMID: 30208410)
Expert Opin Pharmacother. 2023 Sep-Dec;24(17):1887-1899. (PMID: 37691588)
Optom Vis Sci. 2014 Aug;91(8):878-86. (PMID: 24978866)
Ophthalmology. 2013 Apr;120(4):844-51. (PMID: 23332590)
Eye Brain. 2011 Oct 25;3:69-80. (PMID: 28539776)
Diagnostics (Basel). 2023 Dec 10;13(24):. (PMID: 38132220)
Transl Vis Sci Technol. 2021 Nov 1;10(13):14. (PMID: 34757392)
Eye (Lond). 2023 Dec;37(17):3705. (PMID: 37237234)
Rev Neurosci. 2023 Dec 29;35(3):303-330. (PMID: 38153807)
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106. (PMID: 29149325)
J Med Chem. 2006 Jul 27;49(15):4616-22. (PMID: 16854067)
Am J Ophthalmol. 2022 May;237:58-70. (PMID: 34785169)
Retina. 2016 Oct;36(10):1806-22. (PMID: 27652913)
Ann Eye Sci. 2022 Mar 15;7:. (PMID: 37622161)
Neurochem Res. 2010 Nov;35(11):1819-27. (PMID: 20725778)
Ophthalmol Sci. 2023 Aug 13;4(2):100383. (PMID: 37868797)
Invest Ophthalmol Vis Sci. 2017 Apr 1;58(4):2239-2249. (PMID: 28418497)
Nat Commun. 2019 Jul 26;10(1):3347. (PMID: 31350409)
Exp Eye Res. 2024 Jan;238:109728. (PMID: 37972750)
Biomedicines. 2022 Aug 04;10(8):. (PMID: 36009430)
Front Biosci (Schol Ed). 2024 Feb 29;16(1):3. (PMID: 38538345)
PLoS One. 2019 Oct 7;14(10):e0222850. (PMID: 31589624)
Lancet. 2022 Feb 19;399(10326):729-740. (PMID: 35085502)
Ophthalmologica. 1990;200(1):28-38. (PMID: 2320357)
Open Ophthalmol J. 2015 Mar 31;9:36-40. (PMID: 25926902)
PLoS One. 2014 Jun 13;9(6):e100080. (PMID: 24927180)
Exp Anim. 2024 Feb 14;73(1):20-28. (PMID: 37460311)
Sci Rep. 2016 Nov 16;6:37279. (PMID: 27849035)
Br J Pharmacol. 2019 Dec;176 Suppl 1:S21-S141. (PMID: 31710717)
Am J Ophthalmol. 2024 Jul;263:231-239. (PMID: 38387826)
J Vis Exp. 2018 Jan 22;(131):. (PMID: 29443034)
Front Immunol. 2019 May 15;10:1007. (PMID: 31156618)
Lancet Glob Health. 2017 Dec;5(12):e1221-e1234. (PMID: 29032195)
PLoS One. 2016 Oct 24;11(10):e0164899. (PMID: 27776188)
Ophthalmology. 2018 Mar;125(3):369-390. (PMID: 29110945)
Front Cell Dev Biol. 2021 Jan 25;8:612812. (PMID: 33569380)
- Grant Information:
Hamamatsu Pharma Research
- Contributed Indexing:
Keywords: age‐related macular degeneration; avacincaptad pegol; color fundus photography; cynomolgus macaque; fundus autofluorescence; geographic atrophy
- Accession Number:
U558PCS5Z9 (sodium iodate)
0 (Iodates)
- Publication Date:
Date Created: 20241226 Date Completed: 20241226 Latest Revision: 20250214
- Publication Date:
20250214
- Accession Number:
PMC11669843
- Accession Number:
10.1002/prp2.70052
- Accession Number:
39722646
No Comments.